Drug Approval Process

How the Drug Approval Process Works in Canada

Health Canada

Health Canada measures the safety, impact and quality of drugs. After going through this process, a drug can be authorized for sale. Throughout the process, the safety and well-being of Canadians is the paramount concern. It is after a drug is deemed to be safe and have efficacy for patients that a decision is made about how each drug is covered/paid for by provinces and insurers.

pan-Canadian Oncology Drug Review (pCODR) - Patient Voices for Drug Approval

You might be wondering how you can ensure your voice is heard when new medications to treat brain tumours are being approved for funding/coverage by provinces.

Brain Tumour Foundation of Canada is registered with the pan-Canadian Oncology Drug Review (pCODR).  pCODR was established by the provincial and territorial Ministries of Health, excluding Quebec, to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. 

When a drug comes through this process, we will solicit feedback from all patients, survivors and families and will share it with pCODR. To ensure you are in the know about these opportunities, sign up to be an advocate and subscribe to the Advocacy enewsletter.

Once a drug is approved by pCODR it is up to each province to determine if they will cover the cost of the treatment through provincial health plans.

Quebec Cancer Drug Approval Process

Quebec does not participate in the pCODR  process and has its own review process. In Quebec, the Conseil du Médicaments makes the decision regarding medication coverage / reimbursement.

  • Pharmaceutical companies can submit the required medication information to the Conseil du Médicaments for review.
  • For 30 days from the medication submission date, stakeholder groups are given an opportunity to provide their opinions and concerns about the medication funding to the Conseil du Médicaments.
  • The Conseil du Médicaments reviews the medication safety and cost and compares it to other medications funded by the province. After reviewing the information, the Conseil du Médicaments announces the decision regarding coverage / funding. Funding and coverage decision are announced three times annually.
  • Learn more about Conseil du Médicaments on their website.
     

 

Share This

Featured Story

Andrew’s story of being tough

What do you see when you look in the mirror? When Andrew’s friend looked at him, he saw an immensely tough person and wanted to let Andrew know. Andrew wanted to see those words when he looked in the mirror, as his own private message. Andrew has since dedicated his time and energy into setting up a charity to help other cancer patients, incredible for someone battling brain cancer since 2011.

Learn more

Spotlight

Hats for Hope

Today, 8 Canadians will learn they have brain cancer. That's 3,000 Canadians each year. That's why we have launched Hats for Hope a...

Learn more

Childhood Brain Tumour Signs & Symptoms

Earlier this year, you gave us your feedback in a survey on brain tumour signs and symptoms. One of the things we did with that survey...

Learn more

Upcoming Events

  • 19/Nov/2018: Virtual Support Group for Caregivers: Virtual Support Group for Caregivers... Learn more >
  • 19/Nov/2018: Guelph Support Group: Meets at Hospice Wellington, Community Program Room, 795 Scottsdale Avenue,... Learn more >
  • 19/Nov/2018: Mississauga Support Group: Meets at Westminster United Church, 4094 Tomken Rd., Mississauga, ON... Learn more >
  • 19/Nov/2018: Edmonton Support Group: Meets at Wellspring Edmonton, 11306 65 Ave NW, Edmonton, AB ... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2018 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001